Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPeach State Mavyret Coverage Update | OpenPayer
    Ask Trek AI about this page
    ModifiedPeach State Health PlanPolicy GA.PMN.24

    Glecaprevir/Pibrentasvir (Mavyret) coverage

    Customize your policy alerts

    Sign up for Peach State Health Plan Policy GA.PMN.24 alerts

    Get alerted when Policy GA.PMN.24 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity, approval criteria, dosing limits, contraindications, and treatment interruption guidance for Mavyret for Medicaid members. Affects prescribers and pharmacy/medical authorization staff processing prior authorization requests.

    Policy Summary
    PayerPeach State Health Plan
    PolicyGlecaprevir/Pibrentasvir (Mavyret) coverage
    Policy CodePolicy GA.PMN.24
    Change TypeMaterial updates: pediatric expansion, adherence guidance, eligibility wording
    Effective DateSep 17, 2024
    Last ReviewJul 1, 2024
    Next Review DateJul 1, 2024
    Key ActionSubmit prior authorization with documentation of HCV RNA within 6 months, genotype and treatment history, age/weight and cirrhosis status, and prescribed dose within policy limits.
    SourceLink
    POLICY UPDATE CHANGES

    Added Appendix F for guidance on incomplete adherence and AASLD‑IDSA recommended management of treatment interruptions.

    Removed qualifier of 'chronic' from HCV criteria to align with AASLD‑IDSA recommendation to treat both acute and chronic HCV.

    Updated pediatric dosing and added oral pellet formulation for pediatric patients (age expansion to 3 years and older).

    ≥3 yrsminimum age for treatment
    1–6genotypes indicated
    ≤16 wks

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    max approval duration
    within 6 moHCV RNA timing
    Child‑Pugh Aallowed cirrhosis status
    Peds ≥3pediatric age expansion

    Coverage Criteria

    Initial Therapy — Hepatitis C Infection

    Covered when ALL of the following are met:

    Hepatitis C Infection criteria: 1. Diagnosis of HCV infection evidenced by detectable serum HCV RNA by quantitative assay within the last 6 months; 2. Member meets one of: (a) treatment‑naïve with compensated cirrhosis or no cirrhosis OR (b) confirmed HCV genotype as specified by treatment history (treatment‑naïve: genotypes 1–6; prior IFN/pegIFN, RBV, and/or sofosbuvir only: genotypes 1–6; prior NS5A or NS3/4A protease inhibitor experience: genotype 1; prior Vosevi® or Mavyret experience: genotypes 1–6); 3. Age > 3 years; 4. Documentation of treatment status (naïve or experienced); 5. Documentation of cirrhosis status (no cirrhosis, compensated, or decompensated); 6. Life expectancy ≥ 12 months with HCV treatment; 7. Member is not experienced with BOTH an NS3/4A protease inhibitor AND an NS5A inhibitor; 8. Prescribed regimen is consistent with FDA or AASLD‑IDSA recommended regimens; 9. If cirrhosis is present, confirmation of Child‑Pugh A; 10. Member is HBV negative, or if HBV positive, documentation that concurrent HBV infection is being treated unless contraindicated; 11. Dose does not exceed age/weight‑based limits (see dosing criteria).

    Exact genotype and prior‑treatment branching preserved from policy.

    Dosing and coverage by genotype / treatment experience

    Coverage and dosing follow genotype, prior treatment experience, cirrhosis status, and transplantation status per FDA labeling and AASLD‑IDSA recommendations.

    Genotype-based dosing summary: Treatment‑naïve adults/adolescents (age ≥12 years or body weight ≥45 kg) without cirrhosis or with compensated cirrhosis: Mavyret (glecaprevir 300 mg/pibrentasvir 120 mg — 3 tablets) PO once daily for 8 weeks for genotypes 1–6.8 weeks

    Per Dosage and Administration (Appendix F/Table).

    Treatment‑experienced dosing: Treatment‑experienced regimens vary by prior exposure: many patients without prior NS5A exposure may use 8–12 weeks, but genotype 3 and certain prior‑treatment scenarios (e.g., IFN/RBV/sofosbuvir experience) often require extended durations (12–16 weeks) per dosing tables.12–16 weeks depending on scenario

    See treatment‑experienced dosing rows in Dosage and Administration.

    Post‑transplant dosing: Treatment‑naïve or treatment‑experienced post‑liver or kidney transplant patients without cirrhosis or with compensated cirrhosis: dosing per tables; select NS5A‑experienced genotype 1 or genotype 3 prior‑experienced patients may require up to 16 weeks.up to 16 weeks in select cases

    Appendix F / Dosage and Administration references post‑transplant guidance.

    Retreatment for prior DAA failure: For patients with prior sofosbuvir/velpatasvir/voxilaprevir or glecaprevir/pibrentasvir treatment failure and compensated cirrhosis: recommended regimen per AASLD‑IDSA is Mavyret (3 tablets PO QD) plus sofosbuvir 400 mg and weight‑based ribavirin; alternative durations are referenced in AASLD‑IDSA tables.per AASLD‑IDSA guidance

    Refer to Dosage and Administration and AASLD‑IDSA (October 2022) cited in policy.

    Requests for uses that are non‑FDA approved and are not specifically addressed in this policy will not be authorized unless the request is supported by sufficient documentation of efficacy and safety in accordance with the payer's off‑label use policy (CP.PMN.53 for Medicaid) or applicable evidence of coverage documents. Providers requesting coverage for off‑label indications should include supporting clinical evidence and reference the off‑label policy when submitting prior authorization.

    The following diagnoses and indications are explicitly not authorized under this policy: non‑FDA approved indications not addressed in this policy (unless supported per the off‑label use policy) and hepatitis C virus (HCV) in members who are treatment‑experienced with both an NS3/4A protease inhibitor and an NS5A inhibitor (examples include combination regimens such as Technivie, Viekira, and Zepatier). These exclusions were added to the policy during prior updates to reflect available treatment evidence and formulary considerations.

    This clinical policy is intended as a guide to determining medical necessity for Mavyret and related regimens. Actual coverage of services is subject to the terms, exclusions, and limitations of the member's benefit plan and any applicable state or federal coverage requirements. Providers and authorization staff must confirm member eligibility and benefit design; where conflicts exist, Medicaid provisions govern.

    Initial Therapy — Drug-specific Criteria

    Initial Therapy — Drug-specific — Initial therapy coverage requires meeting all Approval Criteria A

    Initial therapy coverage requires meeting ALL of the Approval Criteria (A. Hepatitis C Infection) and adherence to dosing limits.

    Approval Criteria A (drug‑specific context): Refer to the Hepatitis C Infection criteria: HCV RNA within 6 months; appropriate genotype/treatment‑history eligibility; age >3 years; documented cirrhosis status; life expectancy ≥12 months; not experienced with both NS3/4A PI and NS5A inhibitors; regimen consistent with FDA or AASLD‑IDSA; Child‑Pugh A if cirrhosis; HBV management as required; dose within age/weight limits.

    This node duplicates the policy’s A. Hepatitis C Infection requirement in the drug‑specific section.

    Dose limits by age/weight: a) Adults and pediatric ≥12 years or ≥45 kg: glecaprevir 300 mg/pibrentasvir 120 mg (3 tablets) per day; b) Pediatrics 3 to <12 years & <20 kg: glecaprevir 150 mg/pibrentasvir 60 mg per day; c) Pediatrics 3 to <12 years & 20 to <30 kg: glecaprevir 200 mg/pibrentasvir 80 mg per day; d) Pediatrics 3 to <12 years & 30 to <45 kg: glecaprevir 250 mg/pibrentasvir 100 mg per day.

    Maximum dose limits as specified in Approval Criteria A.11.

    Continuation and Interrupted Therapy

    Continuation/Total course — Approval duration and dosing guidance for continuation/total course

    Approval duration and dosing guidance for continuation and total course:

    Approval duration and dosing: Approval duration: up to a total of 16 weeks; continue therapy consistent with the selected regimen in Dosage and Administration (e.g., treatment‑naïve genotypes 1–6 without cirrhosis or with compensated cirrhosis: 3 tablets PO QD for 8 weeks; pediatric weight‑based regimens per dosing tables).up to 16 weeks

    Approved duration should be consistent with a regimen in Section IV Dosage and Administration.

    Interrupted therapy management — Management of interrupted therapy per AASLD‑IDSA (Appendix F)

    Management of interrupted therapy follows AASLD‑IDSA Appendix F recommendations:

    Missed 8–20 days: If missed 8–20 consecutive days, restart direct‑acting antiviral (DAA) therapy immediately and obtain HCV RNA as soon as possible; if HCV RNA is negative, complete the originally planned DAA treatment course (e.g., 8 or 12 weeks). Consider extending treatment by 4 weeks for patients with genotype 3 and/or cirrhosis. If HCV RNA is positive or not obtained, stop treatment and retreat per AASLD‑IDSA retreatment guidance.

    Provider Actions / Prior Authorization Requirements

    Prior Authorization

    Prior authorization required — submit documentation that all Approval Criteria (A.1–A.11) are met

    Prior authorization is required and the provider must submit documentation showing that all Approval Criteria A.1–A.11 are met, including a quantitative serum HCV RNA result within the last 6 months, documented genotype and treatment history, age > 3 years, cirrhosis/Child‑Pugh status, HBV status or treatment, and that the prescribed dose does not exceed the age/weight‑based limits in the policy.

    • Approval Criteria A.1–A.11 must be met
    • HCV RNA (quantitative) within the last 6 months required
    • Dose must be within specified age/weight limits
    Prior Authorization

    Prior authorization must reflect genotype, treatment‑experience, cirrhosis, transplant, and pediatric dosing

    Prior authorization requests must follow the policy’s clinical criteria for dosing and duration based on genotype, prior treatment experience, cirrhosis/Child‑Pugh status, post‑transplant status, and pediatric age/weight thresholds; document prior treatments and genotype where required.

    Coding and Dosing Thresholds

    Weight-based pediatric dosing thresholds
    < 20 kgPediatric weight category: less than 20 kg
    20 to <30 kgPediatric weight category: 20 kg to less than 30 kg
    30 to <45 kgPediatric weight category: 30 kg to less than 45 kg
    Adult/pediatric age/weight threshold
    Age thresholdAge ≥ 12 years
    Weight thresholdBody weight ≥ 45 kg
    Applies to dosing groupAdults and pediatric members ≥12 years or ≥45 kg receive glecaprevir 300 mg / pibrentasvir 120 mg (3 tablets) per day

    Definitions and Scoring

    Child-Pugh class definition and allowed class
    Child-Pugh scoring componentsAssigns points for bilirubin, albumin, INR, ascites, and encephalopathy
    Class A definitionTotal score 5–6 points = Child‑Pugh A (compensated)
    Class B and CTotal score 7–9 = B; 10–15 = C (Mavyret is not for B or C)
    PRS definition — prior treatment experience shorthand
    PRS acronymPRS = prior treatment experience with regimens containing IFN/pegIFN, RBV, and/or sofosbuvir
    Exclusion from PRSNo prior treatment experience with an HCV NS3/4A protease inhibitor or NS5A inhibitor is included in this definition

    Step Therapy / Retreatment Documentation

    StepRequirement / Action
    1Document prior regimen failure when seeking retreatment (e.g., prior sofosbuvir/velpatasvir/voxilaprevir or glecaprevir/pibrentasvir failure). For compensated cirrhosis patients with prior DAA failure, preferred retreatment includes Mavyret (3 tablets PO QD) plus sofosbuvir 400 mg and weight‑based ribavirin per AASLD‑IDSA recommendations (October 2022).

    Quantity Limits

    Mavyret quantity limit
    Quantity limit (tablet strength)Mavyret (glecaprevir 300 mg / pibrentasvir 120 mg): 3 tablets per day
    Maximum daily doseMaximum daily dose limited to 3 tablets (300 mg/120 mg) for adults and eligible pediatric ≥12 years or ≥45 kg
    Reference sectionSee Dosage and Administration for regimen-specific durations (e.g., 8–16 weeks)

    Site of Care

    Billing Rule

    Administration and site of care — oral dosing and outpatient monitoring

    Mavyret is administered orally; dosing and monitoring should follow the outpatient prescriber’s plan and AASLD‑IDSA guidance per the policy’s Dosage and Administration and Appendix F recommendations.

    • Administer as oral tablets (or oral pellet formulation for pediatric patients where applicable).
    • Monitor and manage dosing/duration per outpatient prescriber and AASLD‑IDSA recommendations, including guidance for missed doses in Appendix F.

    Background

    Mavyret is a fixed‑dose combination of the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir indicated for the treatment of hepatitis C virus (HCV) genotypes 1–6 in adults and pediatric patients aged ≥3 years without cirrhosis or with compensated cirrhosis (Child‑Pugh A). The policy aligns dosing and regimen selection with FDA labeling and AASLD‑IDSA guidance, notes available tablet and oral pellet formulations for pediatric use, and incorporates guidance on treatment interruptions and HBV reactivation risk from AASLD‑IDSA resources.

    Policy Summary
    PayerPeach State Health Plan
    PolicyGlecaprevir/Pibrentasvir (Mavyret) coverage
    Policy CodePolicy GA.PMN.24
    Change TypeMaterial updates: pediatric expansion, adherence guidance, eligibility wording
    Effective DateSep 17, 2024
    Last ReviewJul 1, 2024
    Next Review DateJul 1, 2024
    Key ActionSubmit prior authorization with documentation of HCV RNA within 6 months, genotype and treatment history, age/weight and cirrhosis status, and prescribed dose within policy limits.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy — Drug-specific CriteriaContinuation and Interrupted TherapyProvider Actions / Prior Authorization RequirementsCoding and Dosing ThresholdsDefinitions and ScoringStep Therapy / Retreatment DocumentationQuantity LimitsSite of CareBackground

    Initial therapy dosing for treatment‑naive patients

    Treatment‑naïve dosing for eligible patients:

    Treatment‑naïve adults/adolescents: Genotypes 1–6: Without cirrhosis or with compensated cirrhosis: Mavyret three tablets PO once daily for 8 weeks for treatment‑naïve patients meeting age/weight criteria.8 weeks

    Per Dosage and Administration (Appendix F Table).

    8–20 days

    Appendix F guidance.

    Missed ≥21 days: If missed ≥21 consecutive days, stop DAA treatment and assess for SVR12. If SVR12 is not achieved, retreat according to AASLD‑IDSA retreatment recommendations.≥21 days

    Appendix F guidance.

    • Genotype‑ and treatment‑experience–based dosing and durations per Section IV (e.g., 3 tablets PO QD for 8 weeks for many treatment‑naïve adults/adolescents)
    • Pediatric dosing by weight categories and age thresholds (including expansion to ≥3 years) must be used
    Note

    Off‑label use referral — follow off‑label policy CP.PMN.53 when policy does not list the use

    If the requested use is not listed in the policy and the recent label change provision in Section I.B.1 does not apply, providers must refer the request to the off‑label use policy CP.PMN.53 for Medicaid.

    • Use CP.PMN.53 for off‑label requests when not covered in this policy and no recent label change applies
    Step Therapy

    Retreatment — document prior regimen failure and follow preferred retreatment combinations

    When seeking retreatment after prior DAA failure, document the prior regimen and failure; the policy references preferred retreatment combinations (e.g., Mavyret plus sofosbuvir 400 mg and weight‑based RBV for certain compensated cirrhosis cases) per AASLD‑IDSA guidance.

    • Document prior regimen failure when requesting retreatment
    • Preferred retreatment combinations are specified in Appendix/Section IV per AASLD‑IDSA (e.g., Mavyret + sofosbuvir + weight‑based RBV for certain failures)
    Documentation Required

    Documentation submission required — office chart notes and lab results to support criteria

    Provider must submit office chart notes and laboratory results supporting that the member meets the approval criteria, including quantitative serum HCV RNA (detectable) within the last 6 months, genotype, treatment history, cirrhosis status, and prescribed dosing information.

    • Office chart notes and lab results must be provided
    • Include detectable quantitative HCV RNA within 6 months, genotype, treatment history, cirrhosis/Child‑Pugh status, and dosing
    Documentation Required

    Clinical documentation and guideline alignment — reference AASLD‑IDSA and FDA labeling; use pediatric weight/age dosing

    Prescribing must be consistent with FDA labeling and AASLD‑IDSA recommendations; providers should reference AASLD‑IDSA guidance for regimen selection and dosing, and follow the pediatric weight/age dosing tables (including pellet formulation and age expansion to ≥3 years) as provided.

    • Reference most recent AASLD‑IDSA guideline for regimen selection
    • Follow FDA labeling and the policy’s pediatric weight/age dosing tables
    Denial Risk

    Non‑FDA uses and complex prior‑treatment scenarios — may be denied; follow off‑label policy or denials guidance

    Requests for non‑FDA indicated uses that are not addressed in this policy, and complex prior‑treatment scenarios such as members experienced with both an NS3/4A protease inhibitor AND an NS5A inhibitor, are not authorized under this policy unless supported by the off‑label policy or otherwise meet criteria for exception.

    • Non‑FDA indications not in the policy require off‑label policy support (CP.PMN.53)
    • Members experienced with both NS3/4A PI and NS5A inhibitor are excluded unless an exception path is followed
    Note

    Coverage administrative conditions — subject to benefit terms, exclusions, and state/federal requirements

    Coverage is subject to the member’s benefit terms, exclusions, limitations, and applicable state or federal requirements; Medicaid provisions take precedence when in conflict with other program rules.

    • Coverage depends on member benefit documents and may be limited by exclusions
    • State and federal requirements apply; Medicaid provisions prevail if conflicts exist
    Guideline reference
    PRS is used in AASLD/IDSA–aligned dosing tables to denote this specific prior-treatment category